O
30.28
-0.67 (-2.16%)
| Previous Close | 30.95 |
| Open | 30.76 |
| Volume | 687,409 |
| Avg. Volume (3M) | 554,990 |
| Market Cap | 1,418,424,192 |
| Price / Earnings (TTM) | 112.15 |
| Price / Sales | 1.26 |
| Price / Book | 1.14 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 |
| Profit Margin | 1.13% |
| Operating Margin (TTM) | 4.49% |
| Diluted EPS (TTM) | 0.270 |
| Quarterly Revenue Growth (YOY) | 18.60% |
| Quarterly Earnings Growth (YOY) | 55.40% |
| Total Debt/Equity (MRQ) | 30.77% |
| Current Ratio (MRQ) | 1.37 |
| Operating Cash Flow (TTM) | 187.72 M |
| Levered Free Cash Flow (TTM) | 146.87 M |
| Return on Assets (TTM) | 0.16% |
| Return on Equity (TTM) | 1.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | Omnicell, Inc. | Bearish | Mixed |
AIStockmoo Score
0.6
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Average | 0.63 |
|
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 1.69% |
| % Held by Institutions | 101.73% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 62.00 (Benchmark, 104.76%) | Buy |
| Median | 38.00 (25.50%) | |
| Low | 36.00 (JP Morgan, 18.89%) | Hold |
| Average | 45.33 (49.70%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 36.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 17 Apr 2025 | 38.00 (25.50%) | Hold | 30.28 |
| JP Morgan | 20 Mar 2025 | 36.00 (18.89%) | Hold | 34.88 |
| Benchmark | 04 Feb 2025 | 62.00 (104.76%) | Buy | 43.85 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Apr 2025 | Announcement | Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025 |
| 24 Mar 2025 | Announcement | Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer |
| 12 Mar 2025 | Announcement | Omnicell Announces Chief Financial Officer Transition |
| 06 Feb 2025 | Announcement | Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |